Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 17/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MLNR | O43193 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854742 | 1.00 | CACNA1B (0.61) | CACNA1BMEN1KMT2AMLNRNR1I2 | |
| SCHEMBL5856236 | 0.90 | CACNA1B (0.76) | CACNA1BMEN1KMT2AMLNRNR1I2 | |
| SCHEMBL5856241 | 0.90 | CACNA1B (0.76) | CACNA1BMEN1KMT2AMLNRNR1I2 | |
| SCHEMBL5855265 | 0.88 | CACNA1B (0.57) | CACNA1BMEN1KMT2AMLNRNR1I2 | |
| SCHEMBL5855267 | 0.88 | CACNA1B (0.57) | CACNA1BMEN1KMT2AMLNRNR1I2 | |
| SCHEMBL5855158 | 0.88 | CACNA1B (0.79) | CACNA1B | |
| SCHEMBL5855162 | 0.88 | CACNA1B (0.79) | CACNA1B | |
| SCHEMBL5854797 | 0.87 | CACNA1B (0.80) | CACNA1BMEN1KMT2AMLNRNR1I2 | |
| SCHEMBL5854804 | 0.87 | CACNA1B (0.80) | CACNA1BMEN1KMT2AMLNRNR1I2 | |
| SCHEMBL5855568 | 0.87 | CACNA1B (0.69) | CACNA1BMEN1KMT2AMLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995179-B2 | Dihydropyridine derivative | AJINOMOTO CO., INC. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20020111494-A1 | Novel dihydropyridine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-15 | — | — | US | disclosed |
| US-6350766-B1 | PAIN, CNS | AJINOMOTO CO., INC. (JP) | 2002-02-26 | — | — | US | disclosed |
| EP-0985667-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111494-A1 | Novel dihydropyridine derivative | CACNA1B, CACNA1D, CACNA1S | CACNA1B 1/4885MEN1 2700/4885KMT2A 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.